Pharmaceutical Commerce Editorial Staff

The latest news for pharma industry insiders.

According to AbbVie, ImmunoGen's entire oncology portfolio could drive long-term revenue growth, giving the company a potential multi-billion dollar drug that is already on the market.

RLG Healthcare will focus on specialty pharmaceuticals and healthcare packaging.

The pharma powerhouse is investing $300 million in a plant that could be vital for the future cancer trials.

DB Schenker, JAS, Medista, MSC Air Cargo, OnAsset Intelligence, and xpd global round out the latest additions.

The air cargo market numbers close out the year slightly below 2022’s performance.

The acquisition expands Merck’s portfolio in the veterinary pharma space.

Per the deal, the company establishes Regeneron Cell Medicines, while also providing it with access to the collection’s full development and commercialization rights.

As a result, time to treatment for the brand Gilead product is expected to increase from 16 to 14 days.

FDA to evaluate Darzalex Faspro with bortezomib, lenalidomide, and dexamethasone for induction and consolidation treatment and with lenalidomide for the maintenance treatment of adults newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant.

FDA to evaluate Padcev (enfortumab vedotin) with Merck’s Keytruda (pembrolizumab) for the first-line treatment of adults with previously untreated locally advanced or metastatic urothelial cancer.

The pharmaceutical packaging company unveils a new siliconization line at its SQLM plant in France.

Breyanzi is a CD19-directed CAR T-cell therapy approved to treat multiple hematologic cancers.

Gammagard Liquid is now FDA-approved to treat neuromuscular disability and impairment in adults with CIDP; as a replacement treatment for primary immunodeficiency in patients aged 2 years and older; and as a maintenance treatment to improve muscle strength and disability in adults with multifocal motor neuropathy.

The latest financial commitment adds 24,000 liters of biologics drug substance-capacity to the company’s network.

SRP-5051 is a next-generation peptide phosphorodiamidate morpholino oligomer showing promise in the treatment of Duchenne Muscular Dystrophy patients with a confirmed exon 51-amenable mutation.

KEYNOTE-564 is the first Phase III adjuvant trial to show improved survival for renal cancer patients at risk of recurrence after surgery following treatment with Keytruda.

Trial data show Enhertu produced clinically meaningful and durable responses for a survival benefit in patients previously administered treatment for HER2-expressing metastatic solid tumors.

One lot of the company’s branded dextroamphetamine sulfate tablets is being removed from shelves nationwide due to a pharmacy receiving carbinoxamine maleate instead.

GLP-1 agonists may be an effective therapy to avoid severe liver disease in those with concurrent type 2 diabetes.

Dupixent is now the first and only treatment option for eosinophilic esophagitis in patients aged 1 and older, weighing at least 15 kg.

Zynrelef was initially approved by the FDA for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours following bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty.

Tesamorelin (Egrifta) was initially approved by the FDA in November 2010 for the treatment of lipodystrophy in patients also diagnosed with HIV.

FDA adds Boxed Warning that the osteoporosis medication increases the risk for severe hypocalcemia in patients with advanced chronic kidney disease, especially among those undergoing dialysis

Treatments required to have updated warnings include all FDA-approved CAR T-cell therapies and licensed BCMA-directed and CD19-directed genetically modified autologous CAR T-cell immunotherapies.

The FDA assigned Autolus Therapeutics' biologics license application for obecabtagene autoleucel with a Prescription Drug User Fee Act date of November 16, 2024.

The definitive merger agreement was reached in October 2023, with Bristol Myers Squibb acquiring Mirati for $58 per share in cash, for a total equity value of $4.8 billion.

The addressable treatment market for osteopenia is projected to reach more than $30 billion in the United States and $100 billion globally.

Acquisition is expected to strengthen company’s CDMO business, while establishing a footprint in the generics space.

Sandoz will buy Cimerli (ranibizumab-eqrn), an interchangeable biosimilar to Lucentis (ranibizumab), for an upfront cash payment of $170 million.